Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 214

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Open access
Bethge, Wolfgang Andreas, Martus, Peter, Schmitt, Michael, Holtick, Udo, Subklewe, Marion, von Tresckow, Bastian, Ayuk, Francis, Wagner-Drouet, Eva Maria, Wulf, Gerald G, Marks, Reinhard, Penack, Olaf, Schnetzke, Ulf, Koenecke, Christian, von Bonin, Malte, Stelljes, Matthias, Glass, Bertram, Baldus, Claudia D, Vucinic, Vladan, Mougiakakos, Dimitrios, Topp, Max S, Fante, Matthias Alexander, Schroers, Roland, Bayir, Lale May, Borchmann, Peter, Buecklein, Veit, Hanoun, Christine, Thomas, Simone, Beelen, Dietrich W., Lengerke, Claudia, Kroeger, Nicolaus, Dreger, Peter · 2022 · Blood

Abstract

CD19-directed chimeric antigen receptor (CAR) T cells have evolved as new standard-of-care (SOC) treatment in patients with relapsed/refractory large B-cell lymphoma (LBCL). Here, we report the first German real-world data on SOC CAR-T cell therapies with the aim to explore risk factors associated with outcome. Patients who received SOC axicabtagene ciloleucel (axi-cel) or tisagenlecleucel (tisa-cel) for LBCL and were registered with the German Registry for Stem Cell Transplantation (DRST) were eligible. Main outcomes analyzed were toxicities, response, overall survival (OS), and progression-free survival (PFS). We report 356 patients who received axi-cel (n=173) or tisa-cel (n=183) between November 2018 and April 2021 at 21 German centers. Whereas the axi-cel and tisa-cel cohorts were comparable for age, sex, LDH, IPI, and pretreatment, the tisa-cel group comprised significantly more patients with poor performance status, ineligibility for ZUMA-1, and need for bridging, respectively. With a median follow-up alive of 11 months, Kaplan-Meier estimates of OS, PFS, and non-relapse mortality (NRM) 12 months after dosing were 52%, 30%, and 6%, respectively. While NRM was largely driven by infections subsequent to prolonged neutropenia and/or severe neurotoxicity and significantly higher with axi-cel, significant risk factors for PFS on multivariate analysis included bridging failure, elevated LDH, age, and tisa-cel use. In conclusion, this study suggests that important outcome determinants of CD19-directed CAR-T cell treatment of LBCL in the real-world setting are bridging success, CAR-T product selection, LDH, and the absence of prolonged neutropenia and/or severe neurotoxicity. These findings may have implications for designing risk-adapted CAR-T cell therapy strategies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2021015209

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 214

Metadata

Authors
Bethge, W. A., Martus, P., Schmitt, M., Holtick, U., Subklewe, M., von Tresckow, B., Ayuk, F., Wagner-Drouet, E. M., Wulf, G. G., Marks, R., Penack, O., Schnetzke, U., Koenecke, C., von Bonin, M., Stelljes, M., Glass, B., Baldus, C. D., Vucinic, V., Mougiakakos, D., Topp, M. S., Fante, M. A., Schroers, R., Bayir, L. M., Borchmann, P., Buecklein, V., Hanoun, C., Thomas, S., Beelen, D. W., Lengerke, C., Kroeger, N., & Dreger, P.
Venue
Blood
Published
2022-03-22
Volume
140
Issue
4
Pages
349-358
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W4221125141
Cited by
214
References
5
FWCI
18.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. https://app.cochat.ai/papers/10.1182/blood.2021015209
The paper
Bethge, W. A., Martus, P., Schmitt, M., Holtick, U., Subklewe, M., von Tresckow, B., Ayuk, F., Wagner-Drouet, E. M., Wulf, G. G., Marks, R., Penack, O., Schnetzke, U., Koenecke, C., von Bonin, M., Stelljes, M., Glass, B., Baldus, C. D., Vucinic, V., Mougiakakos, D., . . . Dreger, P. (2022). GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany. Blood. https://doi.org/10.1182/blood.2021015209

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.